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Abstract
Background—Among providers who serve low-income and uninsured women, resistance to 
extending the cervical cancer screening interval following normal Pap and co-test results has been 
documented. Our objective was to examine provider characteristics and beliefs associated with 
guideline-consistent screening interval recommendations.
Method—We collected cross-sectional survey data between 2009 and 2010 from 82 primary care 
providers in six Federally Qualified Health Centers in Illinois, USA. The relationships between 
characteristics, beliefs, and screening interval recommendations (1 year vs. 3 years) were tested 
with Pearson chi-square, negative binomial and ordered logistic regression.
Results—Compared to providers who recommended annual intervals after a normal co-test, 
providers who recommended a guideline-consistent (i.e., 3 years) screening interval were 
significantly more likely to report the goodness, ease, and benefit of their recommendation and 
perceived encouragement for a 3-year interval from professional organizations and journals (p < .
05). Providers who recommended a 3-year interval were also less likely to report that longer 
intervals increase patient risk for cervical cancer (p < .05). Interval recommendations were not 
associated with provider specialty, gender, or years in practice.
Conclusion—Messages that promote the benefits of longer screening intervals after a normal 
co-test, the natural history of human papillomavirus and cervical cancer, and low risk of 
developing cancer with a longer interval may be useful to promote evidence-based screening in 
this population of Federally Qualified Health Center providers. Dissemination of targeted 
messages through professional journals and specialty organizations should be considered.
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Introduction
In the United States, screening for cervical cancer is a standard component of women's 
routine preventive healthcare, and has dramatically reduced cervical cancer incidence and 
mortality over the last six decades (Habbema et al., 2012). Current guidelines recommend 
screening intervals of 3 to 5 years following normal test results, based on the screening test 
used. Despite successful integration of cervical cancer screening into women's routine care, 
some uninsured and low-income women are screened less often than recommended and 
suffer disproportionate cervical cancer morbidity, mortality, and late-stage diagnosis 
(Benard et al., 2008; Fedewa et al., 2012; Spence et al., 2007). Conversely, too-frequent 
cervical cancer screening has also been documented in both the medically underserved and 
general population (Corbelli et al., 2014; King et al., 2014; Perkins et al., 2013; Roland et 
al., 2011; Teoh et al., 2015; Verrilli et al., 2014; Yabroff et al., 2009). Plausible explanations 
include opportunistic clinical service provision (Habbema et al., 2012), provider specialty 
(Corbelli et al., 2014; Yabroff et al., 2009), practice setting (Yabroff et al., 2009) and size 
(Perkins et al., 2013), provider concern for losing the patient to follow-up (King et al., 2014; 
Perkins et al., 2013; Verrilli et al., 2014), patient expectations (King et al., 2014; Perkins et 
al., 2013; Teoh et al., 2015; Verrilli et al., 2014), and provider knowledge (Teoh et al., 
2015).
In 2009, the Centers for Disease Control and Prevention (CDC) launched the Cervical 
Cancer (Cx3) Study to examine both provider and patient knowledge, attitudes, and beliefs 
about co-testing (i.e., simultaneous Pap and human papillomavirus testing) and extended 
screening intervals in a medically underserved population (Benard et al., 2014; Hawkins et 
al., 2013; Roland et al., 2013). Baseline survey data collected for the study found that many 
providers recommended annual screening for women after a normal co-test despite 
guidelines at the time recommending a triennial interval. Providers also reported that 
extending the screening interval to three years with a normal co-test would result in the 
patent not returning annually for others tests and losing contact with the medical system 
(Roland et al., 2013). The purpose of the current analysis was to examine what provider 
characteristics and beliefs were associated with their screening interval recommendations 
(annual versus triennial interval) using the baseline survey data.
Method
The Cx3 Study was a pilot study conducted in 15 clinics associated with six Federally 
Qualified Health Centers (FQHCs) in Illinois, USA. In the United States, FQHCs are funded 
by the U.S. Department of Health and Human Services' Health Resources and Services 
Administration (HRSA) under Section 330 of the U.S. Public Health Service Act. FQHCs 
are safety-net clinics, and are mandated to serve an underserved area or population, offer a 
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sliding fee scale, and provide preventive primary care services serve almost 22 million 
patients annually.
In recent years, HRSA-supported FQHCs have received funding to expand operations and 
provide clinical services to a greater number of medically underserved patients (http://
bphc.hrsa.gov/about/healthcenterfactsheet.pdf). Providers working in FQHCs may face 
challenges related to increased patient load, and therefore FQHCs may experience higher 
staff turnover. Incentives to improve recruitment and retention of clinicians in underserved 
areas are being employed (Abrams et al., 2014).
All providers (physicians, nurse practitioners, certified nurse midwives, and physician 
assistants) in the participating clinics who routinely performed cervical cancer screening 
were eligible to participate (n = 109). Between 2009 and 2010, we sent self-administered, 
cross-sectional surveys and a $50 cash incentive to eligible providers with a stamped, self-
addressed envelope for return; 98 providers completed the survey (89.9% response rate).
The survey collected provider demographic characteristics, practice characteristics, and 
screening practices and beliefs. A clinical vignette asked the provider when they would next 
screen a woman aged 35 years with a normal co-test result. Response options were 1 year, 2 
years, 3 years, >3 years. For this analysis, we used responses from the clinical vignette to 
compare the characteristics and beliefs of providers who recommended a 1-year interval (n = 
57) to those of providers who recommended a 3-year interval (n = 25) (guideline-consistent 
at the time of the survey) as a method for defining guideline compliance and non-
compliance. Significance of associations between these two interval recommendations were 
tested with Pearson chi-square, negative binomial and ordered logistic regression. All 
methods adjusted for the clustered sampling design. Missing data was handled with listwise 
deletion. CDC's Institutional Review Board approved the study. Additional details on study 
methods are published elsewhere Benard et al., 2014; Roland et al., 2013.
Results
Providers were primarily female (74%), physicians (67%) or nurse practitioners (21%), 
trained in OB/GYN (56%) or family medicine (35%), with an average of 8.9 years of 
providing clinical care (n = 82). Gender, specialty, provider type, and years in practice were 
not found to be significantly associated with screening interval recommendation (Table 1).
Providers were asked their beliefs about extending screening intervals for a woman aged 
≥30 years with a normal co-test result. Providers who recommended a 3-year interval after a 
normal co-test were more likely to report that extending routine screening to 3 years would 
be good (80%), easy (67%) and beneficial (68%) compared to providers who recommended 
annual screening after a normal co-test (p < .05) (Fig. 1).
Providers were asked to report level of agreement with common concerns about extending 
the screening interval after a normal co-test, including the patient not visiting annually for 
other screening tests, increased risk for the patient developing cervical cancer, higher rates 
of pre-cancer, or the patient losing contact with the medical system. Providers who 
recommended a 3-year interval were significantly more likely to disagree that an extended 
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interval would put the patient at increased risk for cancer (56%) (p < .05) and would result 
in higher rates of pre-cancer (68%) (p= .055) (Table 2).
Providers were asked about their perceived support for extending the screening interval after 
a normal co-test from patients, clinic administration, colleagues, professional specialty 
organizations, national health organizations, and professional journals. Providers who 
recommended a 3-year interval were significantly more likely to perceive support for that 
practice from professional specialty organizations and journals (80%) (p < .05) and national 
health organizations (76%) (p =.051) (Table 2).
Discussion
Despite guidelines recommending longer intervals between cervical cancer screenings, 
women continue to be screened annually. These data identify specific beliefs associated with 
providers guideline-consistent screening interval recommendations, including beliefs about 
the goodness, ease, and benefit of extending screening intervals with a normal co-test result, 
and that extending the interval will not put the patient at increased risk of developing cancer 
or pre-cancer. Disseminating the positive beliefs found to be associated with 3-year intervals 
through professional specialty organizations and professional journals could be effective for 
promoting guideline-consistent interval recommendations among this population, as was 
found in a survey of Indiana primary care providers King et al., 2014. Notably, 
nonmodifiable provider characteristics such as specialty, age, and gender were not 
associated with interval recommendations in this analysis.
Additional methods found to be effective for changing provider's cervical cancer screening 
knowledge, behaviors and attitudes include electronic medical record-based tools (White & 
Kenton, 2013) provider assessment and feedback, Sabatino et al., 2012 and academic 
detailing (Sheinfeld et al., 2000), patient driven inquiry, and management guidelines (King 
et al., 2014). Interventions and messages about cervical cancer screening should prevent the 
harms and risks of routine screening, in addition to the benefits. CDC has produced 
materials to educate providers and patients on the appropriate use of the co-test that may be 
adapted to reflect the needs of the target population and the latest science (Benard et al., 
2014).
To date, no studies have examined provider and patient acceptance of co-testing with longer 
screening intervals in a medically underserved population, and therefore these are novel 
data. Collecting information on beliefs associated with FQHC provider screening interval 
recommendations is essential because as the science evolves, so will screening guidelines 
and screening modalities, and targeting provider beliefs and attitudes will be critical to 
promote uptake of new evidence-based recommendations. Results from this study will assist 
CDC in providing technical assistance to cancer screening programs regarding use of the co-
test. Because of the small convenience sample, these findings may not be generalizable to 
other FQHCs or providers in Illinois. Other limitations include the data were self-reported, 
incentives were provided to complete the survey, and additional details on provider training 
and demographics are unknown.
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Cervical cancer screening in the United States can be improved by reducing the frequency of 
screening intervals for over-screened women to be consistent with guidelines, and directing 
realized savings toward increasing screening among rarely or never-screened women (Kim 
et al., 2013). We found that screening interval recommendations were dictated not by 
provider demographics but by positive beliefs regarding longer screening intervals. While 
this is not surprising, these findings do indicate avenues for dissemination of such beliefs 
that could be promoted and disseminated to counter views about the risks of longer 
screening intervals. Future research regarding how to communicate relative risk and harms 
of over-screening is critical. Provider's perceived risks such as being held accountable for a 
missed diagnosis (Roland et al., 2013), as well as losing the patient to follow-up (Roland et 
al., 2013) and her risk of developing cancer are genuine. The lack of widespread and 
equitable screening participation, particularly among under- and over-screened women, is a 
call to action for public health programs (Plescia et al., 2012). Reducing unnecessary clinical 
intervention is essential when community-based primary care settings with finite resources, 
such as FQHCs, are expected to provide optimal preventive care services to an underserved 
patient population.
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Beliefs about extending cervical cancer screening intervals to 3 years after a normal co-test,a 
according to screening interval recommendations, among 82 providers at Federally 
Qualified Health Centers, Illinois, 2009–2010. Significance of associations between these 
two interval recommendations and beliefs were tested with ordered logistic regression and 
adjusted for clustered sampling design. aCo-test (i.e., simultaneous Pap and human 
papillomavirus test).
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